1AQ Stock Overview
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Evofem Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.18 |
52 Week High | US$7.01 |
52 Week Low | US$0.16 |
Beta | -1.27 |
1 Month Change | 0% |
3 Month Change | 0.55% |
1 Year Change | -96.40% |
3 Year Change | -99.76% |
5 Year Change | n/a |
Change since IPO | -99.87% |
Recent News & Updates
Recent updates
Shareholder Returns
1AQ | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | 2.1% | 1.6% |
1Y | -96.4% | -26.3% | 6.4% |
Return vs Industry: 1AQ underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 1AQ underperformed the German Market which returned 5.9% over the past year.
Price Volatility
1AQ volatility | |
---|---|
1AQ Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1AQ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 1AQ's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 119 | Saundra Pelletier | https://www.evofem.com |
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women.
Evofem Biosciences, Inc. Fundamentals Summary
1AQ fundamental statistics | |
---|---|
Market cap | €7.36m |
Earnings (TTM) | -€264.02m |
Revenue (TTM) | €14.54m |
0.5x
P/S Ratio0.0x
P/E RatioIs 1AQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1AQ income statement (TTM) | |
---|---|
Revenue | US$15.57m |
Cost of Revenue | US$5.06m |
Gross Profit | US$10.51m |
Other Expenses | US$293.21m |
Earnings | -US$282.70m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -2.29 |
Gross Margin | 67.49% |
Net Profit Margin | -1,816.04% |
Debt/Equity Ratio | -55.3% |
How did 1AQ perform over the long term?
See historical performance and comparison